Roche's xCELLigence System and FuGENE® HD Transfection Reagent minimize cytotoxic effects in the detection of bax-induced apoptosis
Liposomal and non-liposomal transfection reagents are the most commonly used carriers for nucleic acid transfer into mammalian cells. However, most transfection reagents exhibit considerable cytotoxic and other side effects on cells. Such cellular off-target responses, if not carefully evaluated, may lead to misinterpretation of results and inaccurate conclusions.
In contrast to the findings for other reagents, FuGENE® HD Transfection Reagent was shown to produce only minimal side effects, while maintaining high transfection efficiency. As a result, FuGENE® HD Transfection Reagent allowed researchers to study the impact of the apoptosis-inducing bax protein, whereas the cytotoxicity and off-target effects of other reagents made it impossible to distinguish the impact of the bax protein from the impact of the transfection reagent itself.
The xCELLigence System monitors cellular events in real time without the incorporation of labels. The System measures electrical impedance across interdigitated micro-electrodes integrated on the bottom of a tissue culture E-Plate. The impedance measurement provides quantitative information about the biological status of the cells, including cell number, viability, and morphology. A wide range of cell-based assays for both high throughput screening and research laboratory environments can be performed on the xCELLigence System.
1. Fila C: Functional Analysis of Side Effects of Transfection Reagents in the Context of Bax-induced Apoptosis. Cellular Analysis Application Note No. 3, 2009; 1-12
Roche Diagnostics Deutschland GmbH
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are protected by law.
XCELLIGENCE is a trademark of Roche.
E-PLATE and ACEA BIOSCIENCES are registered trademarks of ACEA Biosciences, Inc. in the US.
FuGENE is a registered trademark of Fugent, L.L.C., USA